Patents Assigned to Merck
  • Patent number: 6379556
    Abstract: The recovery of iodide from chemical process wastewater is accomplished by loading the wastewater containing iodide onto a strongly basic anion-exchange resin in free-base form; eluting the sorbed iodide from the resin with aqueous strong acid (e.g., hydrochloric acid); loading the iodide-rich cuts onto a weakly basic anion-exchange resin in free-base form; and eluting the sorbed iodide with aqueous base (e.g., sodium hydroxide). The recovered iodide typically has sufficient purity to permit its re-use in the chemical process.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ed Venkat, Ralph J. Magliette, Donald McKinney, Alan S. Michaels
  • Patent number: 6380228
    Abstract: The present invention is directed to peptidomimetic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Craig A. Stump, Theresa M. Williams
  • Patent number: 6380203
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate, Richard L. Kendall, Ruth Rutledge, Kenneth A. Thomas, Jr., Robert Rubino
  • Patent number: 6379758
    Abstract: The invention relates to a liquid crystal display device comprising a liquid crystal cell and at least one compensation film or a combination of polarizer and optical compensators comprising at least one compensation film, said compensation film comprising at least one layer of an isotropic polymer obtainable by polymerization of a mixture of a polymerizable mesogenic material comprising: a) compound having one or two more polymerizable functional group, in the presences b) an initiator, c) optionally a non-polymerizable compound having two or more polymerizable functional groups and d) optionally a stabilizer, characterized in that said layer of an anisotropic polymer has a hometropic or tilted hometropic molecular orientation. The invention also relates to methods of manufacturing said compensation films. The invention further relates to mixtures of chiral polymerizable mesogenic material used for manufacturing of said compensation films.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: April 30, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: James Hanmer, Mark Verrall
  • Patent number: 6380375
    Abstract: The monkey GnRH receptor has been isolated, cloned and sequenced. The monkey GnRH receptor may be used to screen and identify compounds which bind to the GnRH receptor. Such identified compounds may be used in the treatment of sex hormone related conditions such as endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasias such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome and benign prostatic hypertrophy. The receptor proteins and polypeptides, nucleic acids, cells and assays of this invention are useful in drug screening and development, diagnosis and therapeutic applications.
    Type: Grant
    Filed: February 10, 2000
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Jisong Cui, Jane-Ling Lo, George R. Mount
  • Patent number: 6380430
    Abstract: Novel compounds of the formula I in which X, R1, R2, R3, R4 and R5 have the meaning indicated in Patent Claim 1, are inhibitors of the coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: April 30, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkterHaftung
    Inventors: Dieter Dorsch, Horst Juraszyk, Werner Mederski, Joachim Gante, Hanns Wurziger, Hans-Peter Buchstaller, Sabine Bernotat-Danielowski, Guido Melzer
  • Patent number: 6380205
    Abstract: 4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C6alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson, John A. McCauley
  • Patent number: 6380249
    Abstract: Certain six-membered aromatic and heteroaromatic-dioxobutyric acid derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: April 30, 2002
    Assignees: Merck & Co., Inc., Tularik Inc.
    Inventors: Steven D. Young, Melissa Egbertson, Linda S. Payne, John S. Wai, Thorsten E. Fisher, James P. Guare, Jr., Mark W. Embrey, Lekhanh Tran, Linghang Zhuang, Joseph P. Vacca, H. Marie Langford, Jeffrey Melamed, Juan C. Jaen, David L. Clark, Julio C. Medina
  • Patent number: 6380401
    Abstract: Crystalline 3-hydroxylactone-containing products can be prepared in high yield and purity in a one-pot process by treating the corresponding 3,5-dihydroxy acid with a strong mineral acid in a cold, aprotic, water-miscible solvent to effect lactonization, followed by addition of excess acid to effect crystallization of the lactonized product from the reaction mixture.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: James McManus, Nicholas Anousis, John Genus, Christopher Hancock
  • Publication number: 20020049516
    Abstract: The present invention concerns a method of establishing synthesis paths in a multiplicity of potentially interlinkable reactions.
    Type: Application
    Filed: September 5, 2001
    Publication date: April 25, 2002
    Applicant: Merck Patent GmbH
    Inventor: Klemens Bley
  • Publication number: 20020049348
    Abstract: The invention concerns hydrogenated phenanthrenes of formula I 1
    Type: Application
    Filed: June 8, 2001
    Publication date: April 25, 2002
    Applicant: Merck Patent GmbH
    Inventors: Rainer Wingen, Barbara Hornung, Wolfgang Schmidt
  • Patent number: 6376030
    Abstract: Nematic liquid-crystal compositions of negative dielectric anisotropy comprising compounds of the formula I are useful in plasma-addressed liquid-crystal displays.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: April 23, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Michael Heckmeier, Marcus Reuter
  • Patent number: 6376496
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Jeffrey M. Bergman
  • Patent number: 6376509
    Abstract: Certain novel compounds and derivatives thereof are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Raman Kumar Bakshi, Ravi P. Nargund, Zhixiong Ye
  • Patent number: 6376577
    Abstract: The present invention relates to laser-markable plastics which comprise, as dopant, graphite particles having one or more coatings.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck Patentgesellschaft
    Inventors: Helge Kniess, Dieter Heinz, Reiner Delp, Gerhard Pfaff, Matthias Kuntz
  • Patent number: 6376530
    Abstract: The invention encompasses novel compounds of Formula I as well as a method of treating NMDA mediated diseases comprising administration to a patient in need of such treatment a non-toxic amount of a compound of Formula I effective to block the NMDA NR2B receptor sub-unit. The invention also encompasses certain pharmaceutical compositions for the treatment of NMDA mediated diseases comprising compounds of Formula I and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, David A. Claremon
  • Patent number: 6376477
    Abstract: The inhibition of natural bone formation experienced in the prophylaxis and/or treatment of bone resorption disease with a bisphosphonic acid or a pharmaceutically acceptable salt thereof is overcome by the concommitant administration of an agent that binds to the androgen receptor.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Azriel Schmidt, Shun-Ichi Harada, Gideon Rodan
  • Patent number: 6376660
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human NMDA receptor protein subunits and the proteins encoded thereby. The NMDA receptor subunits of the invention comprise components of NMDA receptors that have cation-selective channels and bind glutamate and NMDA. In one aspect of the invention, the nucleic acids encode NMDAR1 and NMDAR2 subunits of human NMDA receptors. In a preferred embodiment, the invention nucleic acids encode NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C and NMDAR2D subunits of human NMDA receptors. In addition to being useful for the production of NMDA receptor subunit proteins, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Lorrie P. Daggett, Chin-Chun Lu
  • Patent number: 6376503
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
    Type: Grant
    Filed: June 17, 1998
    Date of Patent: April 23, 2002
    Assignees: Merck & Co., Inc, Synaptic Pharmaceutical Corporation
    Inventors: Michael A. Patane, Mark G. Bock, Randall C. Newton, Bharat Lagu
  • Patent number: 6376493
    Abstract: A group of compounds of, the preparation of, and the methods of use of benzoylpyridazine derivatives and the physiologically acceptable salts and solvates thereof, which have valuable pharmacological properties while well tolerated. They selectively inhibit phosphodiesterase IV with an intracellular increase in the CAMP level, and have an inhibitory effect on the formation of tumor necrosis factor.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: April 23, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Rochus Jonas, Michael Wolf, Franz-Werner Kluxen